Friday, 20 Apr 2018

You are here

Frequency of Rheumatoid Knee Replacements Down in the Biologic Era

A time-series analysis of incident rheumatoid arthritis (RA) patients seen between 1996 and 2011 in the Danish National Patient Register shows that the incidence of hip (THR) and knee replacements (TKR) began to decrease after the introdution of biologic agents for RA in 2002.

RA patents were matched (age, sex, geography) 1:10 with general population comparators (GPCs). Standardized 5-year incidence rates of THR and TKR surgery were reported from 1996–2001 and compared with the bDMARD era (2003–2016) after the 2002 Danish guidelines introduced biologics for use in RA.

They compared THR and TKR rates between 30 404 RA patients and 297916 GPCs.

Among patients with RA, the incidence rate of TKR increased from 1996 to 2001, but started to decrease from 2003 and throughout the bDMARD era. The incidence of TKR increased among GPCs from 1996 to 2016.

Knee replacement Rates in RA 1996-2012

In 1996, the incidence rate of THR and TKR was 3-fold and 14-fold higher, respectively among patients with RA compared with GPCs in 1996. The introduction of biologics resulted in decreasing TKR rates.

The incidence of THR had started to decrease before bDMARD introduction in 2003.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Shared Epitope - Smoking Pathogenic Link Clarified

Proceedings of the National Academy of Sciences (PNAS) has published new research on the mechanistic link between the rheumatoid arthritis (RA) "shared epitope" (SE) risk alleles and environmental triggers such as cigarette smoke that leads to joint inflammation and bony destruction. 

Kineret Approved for Still's Disease in EU

SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC) for the treatment of Still’s disease (Systemic Juvenile Idiopathic Arthritis [SJIA] and Adult-Onset Still’s Disease [AOSD]), in all 28 European Union (EU) member states. Still's disease is a rare systemic multi-organ disorder of auto-inflammatory nature that affects approximately 25,000 children and adults in the EU.

Mayo and UAB Awarded $1 million Grant for Patient Research

CreakyJoints and Pfizer have selected the Mayo Clinic and the University of Alabama at Birmingham (UAB) to each receive a $500K research award (funded by Pfizer Independent Grants) for Learning & Change.

Grants submitted from both centers haved focused on shared decision making between rheumatoid arthritis (RA) and health care providers.

Defining Refractory Rheumatoid Arthritis

Dr. Maya Buch from Leeds has a thoughtful Viewpoint article in Annals of Rheumatic Disease on how to consider and manage the refractory or difficult rheumatoid arthritis (RA) patient.

Despite advances in our understanding the pathogenesis of RA and the advent of novel biologic and small molecule disease-modifying antirheumatic drugs, we still have a regretful proportion of patients who are refractory to our best therapies.

Uveitis in JIA: Screen All, Treat Early

A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.